381 related articles for article (PubMed ID: 17250725)
1. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
Kapaki EN; Paraskevas GP; Tzerakis NG; Sfagos C; Seretis A; Kararizou E; Vassilopoulos D
Eur J Neurol; 2007 Feb; 14(2):168-73. PubMed ID: 17250725
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease.
Jingami N; Asada-Utsugi M; Uemura K; Noto R; Takahashi M; Ozaki A; Kihara T; Kageyama T; Takahashi R; Shimohama S; Kinoshita A
J Alzheimers Dis; 2015; 45(1):109-15. PubMed ID: 25428256
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis.
Chen Z; Liu C; Zhang J; Relkin N; Xing Y; Li Y
Fluids Barriers CNS; 2017 May; 14(1):13. PubMed ID: 28486988
[TBL] [Abstract][Full Text] [Related]
4. Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus.
Miyajima M; Nakajima M; Ogino I; Miyata H; Motoi Y; Arai H
Eur J Neurol; 2013 Feb; 20(2):236-42. PubMed ID: 22672777
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus versus Alzheimer's Disease and Subcortical Ischemic Vascular Disease: A Systematic Review.
Manniche C; Hejl AM; Hasselbalch SG; Simonsen AH
J Alzheimers Dis; 2019; 68(1):267-279. PubMed ID: 30741681
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.
Kang K; Ko PW; Jin M; Suk K; Lee HW
J Clin Neurosci; 2014 Aug; 21(8):1398-403. PubMed ID: 24836892
[TBL] [Abstract][Full Text] [Related]
7. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
8. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
9. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
11. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
12. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.
Agren-Wilsson A; Lekman A; Sjöberg W; Rosengren L; Blennow K; Bergenheim AT; Malm J
Acta Neurol Scand; 2007 Nov; 116(5):333-9. PubMed ID: 17922727
[TBL] [Abstract][Full Text] [Related]
13. Use of cerebrospinal fluid amyloid-β and total tau protein to predict favorable surgical outcomes in patients with idiopathic normal pressure hydrocephalus.
Tarnaris A; Toma AK; Chapman MD; Keir G; Kitchen ND; Watkins LD
J Neurosurg; 2011 Jul; 115(1):145-50. PubMed ID: 21438653
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study.
Abu-Rumeileh S; Giannini G; Polischi B; Albini-Riccioli L; Milletti D; Oppi F; Stanzani-Maserati M; Capellari S; Mantovani P; Palandri G; Cortelli P; Cevoli S; Parchi P
J Alzheimers Dis; 2019; 68(2):723-733. PubMed ID: 30883350
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease.
Manniche C; Simonsen AH; Hasselbalch SG; Andreasson U; Zetterberg H; Blennow K; Høgh P; Juhler M; Hejl AM
J Alzheimers Dis; 2020; 75(3):937-947. PubMed ID: 32390628
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB
Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias.
Said HM; Kaya D; Yavuz I; Dost FS; Altun ZS; Isik AT
Clin Interv Aging; 2022; 17():467-477. PubMed ID: 35431542
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
